Unravel Biosciences

Unravel Biosciences leverages its proprietary AI-driven BioNAV™ platform to rapidly identify therapeutic mechanisms using patient RNA signatures, systems biology modeling, and rapid in vivo screening. The company focuses on both novel small molecules and repurposing existing drugs. Its approach has led to four clinical trials as of early/mid–2025, including a first-in-class molecule for Rett syndrome with FDA Orphan Drug Designation. Their technology enables efficient derisking of new targets by prototyping treatments directly in patients or relevant models before full-scale development. They report a high hit rate from their predictions compared to traditional phenotypic screens.[1][2][3]